Breaking Finance News

DepoMed (NASDAQ:DEPO) price target bumped up to $27.00, reported earlier today by Mizuho Securities

In an issued report on 9/19/2016 Mizuho Securities raised the target price of DepoMed (NASDAQ:DEPO) from $23 to $27 indicating a possible upside of 0.11%.

Showing a price of $24.34, DepoMed (NASDAQ:DEPO) traded 14.60% higher on the day. With the last stock close up 33.00% relative to the 200-day average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. DEPO has been tracking to a 50-day average of $20.61 and 200-day average of $18.30. 8,542,433 shares of the stock exchanged hands, up from ann avg. trading volume of 1,078,010

Recent Performance Graph:


With a total market value of $0.0, DepoMed has a one-year low of $12.25 and a one-year high of $29.44 with a price-earnings ratio of 0.

In addition to Mizuho Securities reporting it’s stock price target, a total of 11 brokers have issued a research note on DepoMed. The average target price is $23.73 with two analysts rating the company a strong buy, nine analysts rating the company a buy, two firms rating the stock a hold, 0 rating the company to underperform, and finally 0 analystsrating the stock as sell.

Brief Synopsis About DepoMed (NASDAQ:DEPO)

Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company’s products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, and which is used for the management of break through pain in cancer patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *